# A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

> **NCT06023589** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 231 (estimated)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06023589
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-24
- **Primary completion:** 2028-05-31
- **Final completion:** 2030-08-23
- **Target enrollment:** 231 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023589, "A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06023589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*